Intelligent Medicine Exchange (IMX)
|Intelligent Medicine Exchange (IMX)|
|Key People||James Plante, IMX CEO and Co-founder|
The Intelligent Medicine Exchange (IMX) is a proposed exchange that would be the first financial exchange focused on the health care economy, which represents nearly 20% of the U.S. GDP. IMX has filed for regulatory approval with the U.S. Commodity Futures Trading Commission (CFTC) to be a Designated Contract Market (DCM) – a futures exchange focused on contracts that will let individual and institutional market participants manage risk and invest in multiple components of the health care system.
IMX says it has developed proprietary, patent-pending cost indexes that will underlie its futures contracts. It plans to create a transparent, two sided market for pricing of health care assets and provide hedging opportunities for payers and providers and other health care market participants. IMX also said its products would benefit patients through competition for services and through cushioning price shocks in the marketplace, leading to potentially lower prices and premiums.
It is a subsidiary of the holding company IMX, LLC.
In June 2022, IMX announced that they had entered into an agreement for the Minneapolis Grain Exchange (MGEX) to provide clearing services to IMX for certain cash-settled futures and options on futures contracts. The services will include managing exposures, clearing trades, and collecting and maintaining performance bonds and security deposits for participants.
Products and Services
- Eileen Flaherty, IMX Board member and strategic advisor
- Gregory C. Simon, Board member and Co-founder of IMX